Evidence map›Paper›PMID 29209802›Full record

ReviewZeitschrift fur Gerontologie und Geriatrie2018

[Doping for the brain].

Bernhard Iglseder

Abstract readReview
PubMed Publisher
In one paragraph

Review in Zeitschrift fur Gerontologie und Geriatrie, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Bernhard IglsederChristian-Doppler-Klinik, Universitätsklinik für Geriatrie der PMU, Uniklinikum Salzburg, Ignaz-Harrer-Str. 79, 5020, Salzburg, Österreich. b.iglseder@salk.at.ORCID http://orcid.org/0000-0002-6132-8670

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The enhancement of physical and cognitive abilities (i. e. concentration, vigilance, memory) has always been desirable for humans. The term pharmacological neuroenhancement refers to the use of legal or nonprescription psychoactive substances by healthy subjects with the intention of cognitive enhancement. To give the most prominent example, caffeine serves worldwide as a natural stimulant. Brain doping, however, specifies the use of illegal substances or prescription drugs beyond approval with the purpose of cognitive enhancement. Only amphetamines, methylphenidate and modafinil have significant effects on attentiveness, concentration and alertness, whereas other substances, such as anti-dementia drugs or anti-depressants failed to demonstrate cognitive enhancement in healthy subjects.

Indexed as

Cognitive AgingSubstance-Related DisordersAgedAmphetaminesBrainDietary SupplementsHumansIllicit DrugsMethylphenidateModafinilNootropic AgentsPlant PreparationsPrescription DrugsPsychotropic DrugsAmphetaminesIllicit DrugsMethylphenidateModafinilNootropic AgentsPlant PreparationsPrescription DrugsPsychotropic DrugsBrain dopingCognitionEnhancementNeuroenhancementPsychotropic drugs

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.